The data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in Genitope’s pivotal phase III clinical trial in follicular non-Hodgkin’s lymphoma (fNHL) and recommended that the study continue as planned.
This trial is evaluating the safety and efficacy of the company’s lead product candidate, MyVax personalized immunotherapy, in patients with previously untreated fNHL. It compares patients treated with MyVax to patients treated with a non-specific immunotherapy control.
The trial is expected to be completed by December 2007.